Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Eur Urol. 2018 May 28;74(4):444–452. doi: 10.1016/j.eururo.2018.05.014

Table 3.

– Genomic risk and clusters as predictors of outcomes

Adverse pathology
 Biochemical recurrence
OR (95% CI) p value HR (95% CI) p value
CAPRA 1.54 (1.14–2.07)  0.004 1.14 (0.72–1.80)  0.6
PSA density 1.16 (0.92–1.45)  0.2 1.32 (0.99–1.63)  0.06
AGR 1.23 (1.03–1.47)  0.02 1.58 (1.21–2.03)  0.001
CAPRA 1.65 (1.23–2.22)  <0.001 1.20 (0.75–1.90)  0.4
PSA density 1.14 (0.9–1.43)  0.3 1.28 (0.95–1.60)  0.1
Genomic cluster 1 REF REF
Genomic cluster 2 1.19 (0.61–2.28)  0.6 1.17 (0.45–2.96)  0.7
Genomic cluster 3 1.78 (0.98–3.23)  0.06 0.95 (0.35–2.46)  0.9

AGR = average genomic risk; CI = confidence interval; CAPRA = Cancer of the Prostate Risk Assessment; HR = hazard ratio; OR = odds ratio; REF = reference. Adverse pathology outcomes are based on multivariable logistic regression and biochemical recurrence outcomes are based on Cox proportional hazards regression.